

(19)



(11)

EP 1 709 044 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
16.07.2008 Bulletin 2008/29

(51) Int Cl.:
C07D 471/04 (2006.01)

(21) Application number: **04804099.2**

(86) International application number:
PCT/EP2004/014500

(22) Date of filing: **20.12.2004**

(87) International publication number:
WO 2005/058888 (30.06.2005 Gazette 2005/26)

(54) OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS

OXAZOLIDINON-CHINOLON HYBRID ANTIBIOTIKA

ANTIBIOTIQUES HYBRIDES A BASE D'OXAZOLIDINONE-QUINOLONE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**

- **SCHMITT, Christine**
F-68320 Kunheim (FR)
- **MÜLLER, Stefan**
5036 Oberentfelden (CH)
- **CAPPI, Michael**
81369 München (DE)

(30) Priority: **18.12.2003 US 530822 P**
23.01.2004 EP 04001506

(43) Date of publication of application:
11.10.2006 Bulletin 2006/41

(74) Representative: **Forstmeyer, Dietmar et al**
BOETERS & LIECK
Oberanger 32
80331 München (DE)

(73) Proprietor: **Morphochem Aktiengesellschaft Für
Kombinatorische
Chemie**
81379 München (DE)

(56) References cited:
WO-A-02/059116 WO-A-03/002560
WO-A-03/031443 WO-A-03/032962

(72) Inventors:

- **HUBSCHWERLEN, Christian**
F-68480 Durmenach (FR)
- **SPECKLIN, J. L.**
68680 Kembs-Schaeferhof (FR)
- **BAESCHLIN, Daniel, Kaspar**
CH-4144 Arlesheim (CH)

Remarks:

The file contains technical information submitted after
the application was filed and not included in this
specification

EP 1 709 044 B1


Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention describes new compounds in which the pharmacophores of quinolone and oxazolidinone are linked together through a linker that is stable under physiological conditions and a pharmaceutical antibacterial composition containing these compounds. These dual action compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including Gram positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as Gram negative bacteria such as *Moraxella catarrhalis* and *Haemophilus influenzae* and anaerobic organisms such as *Bacteroides* spp. and *Clostridia* spp. species and acid-fast organism such as *Mycobacterium tuberculosis*, *Mycobacterium avium* spp.

[0002] Oxazolidinone-quinolone hybrid antibiotics have already been described (WO02059116, WO03002560, WO03031443, WO03032962). The major drawback of the compounds known in the state of the art is the poor water solubility, which makes the development of a formulation difficult.

[0003] The present invention provides new compounds of formula (I), that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria



wherein

A is an alkylene group, an alkenylene group, an alkynylene group, a heteroalkylene group, a cycloalkylene group, a heterocycloalkylene group, an arylene group or a heteroarylene group all of which groups may be substituted;

Q is CR⁴;

X is CR⁷ or N;

Y is CR⁶ or N;

n is 1, 2 or 3;

m is 1, 2 or 3;


R¹ is H, F, Cl, Br, I, OH, NH₂, an alkyl group or a heteroalkyl group;

R² is H, F or Cl;

R³ is H, an alkyl group, an alkenyl group, an alkynyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalkyl group; all of which groups may be substituted with one, two or more halogen atoms like F or Cl or amino groups.

R⁴ is hydroxy, a group of formula OPO₃R⁹₂ or OSO₃R¹⁰ or a heteroalkyl group carrying at least one OH, NH₂, SO₃R¹⁰, PO₃R⁹₂ or COOH group or an ester of a naturally occurring amino acid or a derivative thereof, wherein the groups R⁹ independently of each other are H, alkyl, cycloalkyl, aryl or aralkyl and wherein R¹⁰ is H, alkyl, cycloalkyl, aryl or aralkyl;

R⁵ is selected from following groups:



R⁶ is H, F, Cl or OMe;

R⁷ is H, F, Cl, OH, NH₂, a substituted or unsubstituted alkyl group or a substituted or unsubstituted heteroalkyl group, or R³ and R⁷ can be linked via an alkylene, an alkenylene or a heteroalkylene group or be a part of a cycloalkylene or heterocycloalkylene group; in case R³ is no H and R⁷ is no H, F, OH, NH₂ or Cl; and

R⁸ is a C₁₋₆ heteroalkyl, a heteroarylalkyl, a heteroalkylaryl or a heteroalkylheteroaryl group; or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

[0004] It should be appreciated that certain compounds of formula (I) or (II) as mentioned in this description may have tautomeric forms from which only one might be specifically mentioned or depicted in this description, different geometrical isomers (which are usually denoted as cis/trans isomers or more generally as (E) and (Z) isomers) or different optical isomers as a result of one or more chiral carbon atoms (which are usually nomenclatured under the Cahn-Ingold-Prelog or R/S system). Further, some compounds may display polymorphism. All these tautomeric forms, geometrical or optical isomers (as well as racemates and diastereomers) and polymorphous forms are included in the invention.

[0005] The term alkyl refers to a saturated straight or branched chain alkyl group, preferably containing from one to ten, preferably one to six carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, n-hexyl, 2,2-dimethylbutyl, n-octyl or n-pentyl groups. Any alkyl group as defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, NH₂, OH, SH or NO₂.

[0006] The terms alkenyl and alkynyl refer to an unsaturated straight or branched chain alkyl group (having one, two or more double and/or triple bonds, an alkenyl preferably having one or two double bonds and an alkynyl preferably having one or two triple bonds), preferably containing two to ten, preferably two to six carbon atoms for example: ethenyl (vinyl), propenyl (allyl), iso-propenyl, n-pentenyl, butenyl, isoprenyl or hexa-2-enyl; ethynyl, propynyl or butynyl groups. Any alkenyl or alkynyl group as defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, NH₂, OH, SH or NO₂.

[0007] The term heteroalkyl refers to an alkyl, alkenyl or alkynyl group as defined herein where one or more carbon atoms are replaced by an oxygen, nitrogen, phosphorous or sulphur atom, for example an alkoxy group such as methoxy, ethoxy, propoxy, iso-propoxy, butoxy or tert.-butoxy, an alkoxyalkyl group such as methoxymethyl, ethoxymethyl, 1-methoxyethyl, 1-ethoxyethyl, 2-methoxyethyl or 2-ethoxyethyl, an alkylamino group such as methylamino, ethylamino, propylamino, isopropylamino, dimethylamino or diethylamino, an alkylthio group such as methylthio, ethylthio or isopropylthio or a cyano group. It may also refer to one of the above groups containing a keto group. The term heteroalkyl furthermore refers to a group derived from a carboxylic acid or carboxylic acid amide such as acetyl, propionyl, acetyloxy, propionyloxy, acetyl amino or propionyl amino, a carboxyalkyl group such as carboxymethyl, carboxyethyl or carboxypropyl, a carboxyalkyl ester, an alkylthiocarboxyamino group, an alkoxyimino group, an alkylaminothiocarboxyamino group or an alkoxy carbonylamino group. Any heteroalkyl group as defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, NH₂, OH, SH or NO₂.

[0008] The term cycloalkyl refers to a saturated or partially unsaturated (having one, two or more double and/or triple bonds) cyclic group with one, two or more rings, having three to 14 carbon ring-atoms, preferably from five or six to ten carbon ring-atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetralin, cyclopentenyl or cyclohex-2-enyl groups. Any cycloalkyl group as defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, OH, NH₂, SH, N₃, NO₂, alkyl groups such as methyl or ethyl, heteroalkyl groups such as methoxy, methylamino, dimethylamino or cyanide.

[0009] The term heterocycloalkyl refers to a cycloalkyl group as defined herein where one, two or more carbon ring-atoms are replaced by one, two or more oxygen, nitrogen, phosphorous or sulphur atoms or S(0)₁₋₂ groups for example piperidino, morpholino or piperazino groups.

[0010] The term aryl refers to an aromatic cyclic group with one, two or more rings, having five to 14 carbon ring-atoms preferably from five or six to ten carbon ring-atoms, for example phenyl or naphthyl groups. Any aryl group as defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, OH, NH₂, SH, N₃, NO₂, alkyl groups such as methyl or ethyl, heteroalkyl groups such as methoxy, methylamino, dimethylamino or cyanide.

[0011] The term heteroaryl refers to an aryl group as defined herein where one, two or more ring-carbon atoms are replaced by an oxygen, nitrogen, boron, phosphorous or sulphur atom, for example pyridyl, imidazolyl, pyrazolyl, quinolinyl, isoquinolinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, tetrazolyl, pyrazinyl, pyrimidinyl and pyridazinyl groups.

[0012] The term aralkyl (or arylalkyl or alkylaryl) refers to groups that comprise both aryl as well as alkyl and/or cycloalkyl groups.

[0013] The term heteroarylalkyl (or heteroalkylaryl or heteroalkylheteroaryl etc.) refers to an aralkyl group as defined herein where one, two, three or more carbon atoms are replaced by one, two, three or more oxygen, nitrogen, phosphorous or sulphur atoms or S(0)₁₋₂ groups.

[0014] Any alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl or heteroarylalkyl groups as defined herein may be substituted with one or more halogen atoms, NH₂, SH, NO₂ or OH groups or unsubstituted alkyl, heteroalkyl, aryl, aralkyl, aralkyloxy, heteroaryl, cycloalkyl or heterocycloalkyl groups as defined herein.

[0015] The term "optionally substituted" or "substituted" refer to groups wherein one or more hydrogen atoms may be replaced by a halogen atom, a NH_2 , SH , NO_2 or OH group or by an unsubstituted alkyl, heteroalkyl, aryl, aralkyl, aralkyloxy, heteroaryl, cycloalkyl or heterocycloalkyl group as defined herein.

[0016] Preferred and/or advantageous embodiments of the invention are subject-matter of the subclaims.

[0017] Preferred are compounds of Formula (I), wherein R^1 is H.

[0018] Further preferred are compounds of Formula (I), wherein R^2 is F or H.

[0019] Moreover preferred are compounds of Formula (I), wherein R^3 is an ethyl, a 2-propyl, a $\text{C}_3\text{-C}_6$ cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), a phenyl or a pyridyl group. All these groups may be substituted with one, two, three or more fluorine atoms or amino groups.


[0020] Moreover preferred are compounds of Formula (I), wherein R^3 is a cyclopropyl group.

[0021] Further preferred are compounds of Formula (I), wherein R^7 and R^3 together form a bridge of the formula $-\text{O}-\text{CH}_2-\text{N}(\text{Me})-$ or $-\text{O}-\text{CH}_2-\text{CH}(\text{Me})-$. Herein, the preferred stereochemistry at the chiral center is the one giving the (S) configuration in the final compound.

[0022] Moreover preferred are compounds of formula (I), wherein R^4 is hydroxy or a group of formula OSO_3H , OPO_3H_2 , $\text{OCH}_2\text{OPO}_3\text{H}_2$, $\text{OCOCH}_2\text{CH}_2\text{COOH}$ or an ester of a naturally occurring amino acid or a derivative thereof (i.e. a group of formula $-\text{OCOCHR}'\text{NH}_2$ or a derivative like an ester, amide or alkylamine thereof, wherein R' is the side chain of a naturally occurring amino acid like aspartic acid, glutaric acid, lysine, etc; e.g. dimethyl aminoglycine $\text{OCOCH}_2\text{N}(\text{CH}_3)_2$).

[0023] Further preferred are compounds of Formula (I), wherein R^8 is a group of the formula $-\text{CH}_2\text{NHCOCH}=\text{CHAr}$, $-\text{CH}_2\text{OHeteroaryl}$ (especially $-\text{oxa-3-oxazol}$), $-\text{CH}_2\text{NHSO}_2\text{Me}$, $-\text{CH}_2\text{NHCOOMe}$, $-\text{CH}_2\text{NHCOMe}$, $-\text{CH}_2\text{NHCS}_2\text{Me}$, $-\text{CH}_2\text{NHCSMe}$, $-\text{CH}_2\text{NHCSNH}_2$, $-\text{CH}_2\text{NHCSOMe}$ or $-\text{NHCOMe}$; especially $-\text{CH}_2\text{NHCSMe}$ or $-\text{CH}_2\text{NHCOMe}$.

[0024] Especially preferred are compounds of Formula (I), wherein R^5 has the following structure:



[0025] Moreover preferred are compounds of Formula (I), wherein R^7 is H, F, Cl or a methoxy group that may be substituted by one, two or three fluorine atoms.

[0026] Further preferred are compounds of formula (I), wherein X is N or CH.

[0027] Moreover preferred are compounds of Formula (I), wherein Y is CH or N.


[0028] Further preferred are compounds of Formula (I), wherein A is C_{1-6} alkylene, C_{2-6} alkenylene, C_{2-6} alkynylene, C_{1-6} heteroalkylene, cyclopropylene, epoxide, aziridine, thioepoxide, lactame or lactone, all of which groups may be substituted.

[0029] Moreover preferred are compounds of formula (I), wherein A is a group of Formula $-\text{O}-\text{B}-$, wherein B is a C_{1-4} alkylene group, a C_{2-4} alkenylene group, a C_{2-4} alkynylene group or a C_{1-4} heteroalkylene group, all of which groups may be substituted by one, two or more hydroxy or amino groups.

[0030] Especially preferred are compounds of formula (I), wherein A is a group of formula $-\text{CH}_2\text{CH}_2-$, $-\text{OCH}_2-$, $-\text{OCH}_2\text{CH}_2-$, $-\text{SCH}_2-$, $-\text{SCH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{CH}(\text{OH})\text{CH}(\text{OH})-$ or $-\text{CH}(\text{NH}_2)\text{CH}(\text{OH})-$.

[0031] Especially preferred are compounds of formula (I), wherein B is CH_2 or CH_2CH_2 .

[0032] Especially preferred are compounds of formula (II)



wherein the residues are defined as above. In a preferred embodiment B is CH_2 or CH_2CH_2 ; X is CH, N or C-OMe and R^3 is cyclopropyl or X is CR^7 and R^7 and R^3 together form a bridge of the formula $-\text{O}-\text{CH}_2-\text{CH}(\text{Me})-$, wherein the preferred stereochemistry at the chiral center is the one giving the (S) configuration in the final compound, n is 1, 2 or 3, m is 1, 2 or 3 and R^4 is hydroxy or a group of formula OSO_3H , OPO_3H_2 , $\text{OCH}_2\text{OPO}_3\text{H}_2$, $\text{OCOCH}_2\text{CH}_2\text{COOH}$ or an ester of a naturally occurring amino acid or a derivative thereof.

[0033] Moreover preferred are the mono, di or tri sodium salts (most preferred the mono sodium salts) of compounds of formula (I) or (II) or mixtures thereof. Especially preferred are the mono, di or tri sodium salts (most preferred the mono sodium salts) of compounds of formula (I) or (II), wherein R^4 is OPO_3H_2 or OSO_3H or mixtures thereof.

[0034] Especially preferred is the sodium salt of a compound of formula (II) wherein R^3 is a cyclopropyl group, X is CH or N, n is 2, m is 2, R^4 is OPO_3H_2 and B is CH_2 .

[0035] The present invention also relates to pharmacologically acceptable salts, or solvates and hydrates, respectively, and to compositions and formulations of compounds of Formula (I) or (II). The present invention describes procedures to produce pharmaceutically useful agents, which contain these compounds, as well as the use of these compounds for the production of pharmaceutically useful agents.


[0036] The pharmaceutical compositions according to the present invention contain at least one compound of Formula (I) or (II) as the active agent and optionally carriers and/or diluents and/or adjuvants. Optionally the pharmaceutical compositions according to the present invention may also contain additional known antibiotics.

[0037] Examples of pharmacologically acceptable salts of sufficiently basic compounds of Formula (I) or (II) are salts of physiologically acceptable mineral acids like hydrochloric, hydrobromic, sulfuric and phosphoric acid; or salts of organic acids like methanesulfonic, p-toluenesulfonic, lactic, acetic, trifluoroacetic, citric, succinic, fumaric, maleic and salicylic acid. Further, a sufficiently acidic compound of Formula (I) or (II) may form alkali or earth alkaline metal salts, for example sodium, potassium, lithium, calcium or magnesium salts; ammonium salts; or organic base salts, for example methylamine, dimethylamine, trimethylamine, triethylamine, ethylenediamine, ethanolamine, choline hydroxide, meglumin, piperidine, morpholine, tris-(2-hydroxyethyl)amine, lysine or arginine salts. Compounds of Formula (I) or (II) may be solvated, especially hydrated. The hydration can occur during the process of production or as a consequence of the hygroscopic nature of the initially water free compounds of Formula (I) or (II). The compounds of Formula (I) or (II) may contain asymmetric C-atoms and may be present either as achiral compounds, mixtures of diastereomers, mixtures of enantiomers or as optically pure compounds.

[0038] As mentioned above, therapeutically useful agents that contain compounds of Formula (I) or (II), their solvates, salts or formulations are also comprised in the scope of the present invention. In general, compounds of Formula (I) or (II) will be administered by using the known and acceptable modes known in the art, either alone or in combination with any other therapeutic agent. Such therapeutically useful agents can be administered by one of the following routes: oral, e.g. as tablets, dragees, coated tablets, pills, semisolids, soft or hard capsules, for example soft and hard gelatine capsules, aqueous or oily solutions, emulsions, suspensions or syrups, parenteral including intravenous, intramuscular and subcutaneous injection, e.g. as an injectable solution or suspension, rectal as suppositories, by inhalation or insufflation, e.g. as a powder formulation, as microcrystals or as a spray (e.g. liquid aerosol), transdermal, for example via an transdermal delivery system (TDS) such as a plaster containing the active ingredient or intranasal. For the production of such tablets, pills, semisolids, coated tablets, dragees and hard, e.g. gelatine, capsules the therapeutically useful product may be mixed with pharmaceutically inert, inorganic or organic excipients as are e.g. lactose, sucrose, glucose, gelatin, malt, silica gel, starch or derivatives thereof, talc, stearic acid or their salts, dried skim milk, and the like. For the production of soft capsules one may use excipients as are e.g. vegetable, petroleum, animal or synthetic oils, wax, fat, polyols. For the production of liquid solutions, emulsions or suspensions or syrups one may use as excipients e.g. water, alcohols, aqueous saline, aqueous dextrose, polyols, glycerin, lipids, phospholipids, cyclodextrins, vegetable, petroleum, animal or synthetic oils. Especially preferred are lipids and more preferred are phospholipids (preferred of natural origin; especially preferred with a particle size between 300 to 350 nm) preferred in phosphate buffered saline (pH = 7 to 8, preferred 7.4). For suppositories one may use excipients as are e.g. vegetable, petroleum, animal or synthetic oils, wax, fat and polyols. For aerosol formulations one may use compressed gases suitable for this purpose, as are e.g. oxygen, nitrogen and carbon dioxide. The pharmaceutically useful agents may also contain additives for conservation, stabilisation, e.g. UV stabilizers, emulsifiers, sweetener, aromatisers, salts to change the osmotic pressure, buffers, coating additives and antioxidants.

[0039] A daily dosage per patient of about 1mg to about 4000mg especially about 50mg to 3 g is usual with those of ordinary skill in the art appreciating that the dosage will depend also upon the age, conditions of the mammals, and the kind of diseases being treated or prevented. The daily dosage can be administered in a single dose or can be divided over several doses. An average single dose of about 50mg, 100mg, 250mg, 500mg, 1000mg and 2000mg can be contemplated.

[0040] The compounds of formula (I) and (II) can be synthesized according to the following reaction scheme:




reaction conditions:

[0041] step 1: CH_2Cl_2 , KOH (50%), 3h, rt; 97%. step 2: H_2 , Pt/C, 20h, rt; followed by Z-Cl (Cbz-Cl), acetone/water, NaHCO_3 , 12h, rt, 98%. step 3: n-BuLi, -60°C , 24h, 80%. step 4: MsCl, triethylamine, CH_2Cl_2 ; 100%. step 5: NaN_3 in DMF, 90°C , cat. Bu_4NI , 5h, 90%. step 6: H_2 , $\text{Pd}(\text{OH})_2$, THF, MeOH, 24h, followed by AcOH, AC_2O , rt, 2h, 70%. step 7: DMF, NaH, 70°C , 12h, 75%. step 8: H_2 , $\text{Pd}(\text{OH})_2$, MeOH, THF, 24h, RT, 100%. step 9: N-Methylpyrrolidinone, 1-Cyclopropyl-7-chloro-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthydrin-3-carboxylic acid (commercially available), TMS-Cl, Hünig Base or K_2CO_3 , 80°C , 5h, 80%.

Examples

Example 1: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid

[0042]



Step 1: (4-Benzyloxy-3-fluoro-phenyl)-carbamic acid benzyl ester:

[0043] A solution of 34.9g 1-benzyloxy-2-fluoro-4-nitro-benzene (WO03064413) (MW:247.28, 141mmol) and 340mg platinum 5% on activated carbon in 350ml ethyl acetate was stirred under hydrogen at rt and normal pressure. The reaction was monitored by HPLC and was complete after twenty hours. The catalyst was filtered over a glass fiber filter, and the filtrate evaporated under reduced pressure to dryness. The oily residue was dissolved in 500ml acetone and treated with 250ml of a saturated solution of sodium bicarbonate and 17.5g of sodium bicarbonate (MW: 84.01, 208mmol). The mixture was cooled to 5°C and treated drop wise with 26.08g of benzyl chloroformate (MW:170.59, 152mmol). The reaction was allowed to stirred at room temperature for two hours and monitored by TLC (hexane/ethyl acetate 3:1). The acetone was evaporated, the residue diluted with 500ml water, and the solid filtered off. The crystals were washed with 500ml water and dried. Yield: 48.05g, 95.8%. MS: 352.5 (M+H)⁺, 350.8, (M-H)⁻. Method ESI⁺, ESI⁻.

Step 2: (5R)-3-(4-benzyloxy-3-fluoro-phenyl)-5-hydroxymethyl-oxazolidin-2-one:

[0044] A stirred solution of 17.5g (4-benzyloxy-3-fluoro-phenyl)-carbamic acid benzyl ester (MW: 351.38, 50mmol) in 30ml of dry tetrahydrofuran was cooled to -78°C with a dry ice/acetone bath. 22.8ml of a 2.3M n-butyl-lithium solution in n-hexane (52.5mmol) was added drop wise and the reaction mixture stirred at -78 °C for 15 min. 7.92g *R*(-)-glycidyl butyrate (MW: 144.17, 60mmol) were added and the reaction was allowed to warm up to room temperature. The reaction was monitored by HPLC, quenched with a saturated ammonium chloride solution and diluted with 100ml of ethyl acetate. The organic layer was washed with 200ml water and 200ml brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate evaporated under reduced pressure. The residue was crystallized from 200ml of a 1/1-ethyl acetate/hexane mixture. The solid was collected and recrystallized from 150ml of a 9/1 ethyl acetate/dichloro-methane mixture. The colorless crystals were collected and dried. Yield: 10.4-g, 65.5%. MS: 318.1 (M+H)⁺. Method ESI⁺.

Step 3: (5S)-5-azidomethyl-3- (4-benzyloxy-3-fluorophenyl)-oxazolidin-2-one:

[0045] A solution of 10g (5R)-3-(4-benzyloxy-3-fluoro-phenyl)-5-hydroxymethyl-oxazolidin-2-one (MW: 317.32, 31.51mmol) and 4.78g triethylamine (MW: 101.19, 47.26mmol) in 300ml dichloromethane was treated under stirring at 10°C with 4.32g of methane sulfonyl chloride (MW: 114.55, 37.82mmol). The reaction was stirred at room temperature for one hour and monitored by TLC (ethyl acetate: hexane 1:1). The reaction mixture was quenched with 100ml water and the organic layer washed with 100ml brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate evaporated under reduced pressure. The residue was dissolved in 100ml dimethylformamide, 5.12g sodium azide (MW: 65.01, 78.7mmol) and a catalytic amount of tetrabutyl ammonium iodide were added. The suspension was stirred at 90 °C over night. The reaction was monitored by HPLC. The dimethylformamide was evaporated under reduced pressure, the residue dissolved in 200ml dichloromethane and the organic layer washed successively with 100ml water and 100ml brine. The dichloromethane solution was dried over magnesium sulfate, filtered, and the filtrate evaporated under reduced pressure. The residue was crystallized from 150ml of a 1/1 mixture of ethyl acetate: hexane. The crystals were collected to afford an off white solid. Yield: 10.4-g, 97%. MS: 343.1 (M+H)⁺. Method: ESI⁺.

Step 4: N-[(5S)-{3-(3-fluoro-4-hydroxy-phenyl)}-2-oxo-oxazolidin-5-ylmethyl]-acetamide:

[0046] A suspension of 10.4g (5S)-5-azidomethyl-3- (4-benzyloxy-3-fluorophenyl)oxazolidin-2-one (MW: 342.33, 30.38mmol) and 1.5g of palladium 10% on activated carbon in 400ml of a 1:1 methanol:ethyl acetate mixture was stirred at room temperature under hydrogen for two days. The catalyst was filtered off using a glass fibre filter paper and the filtrate evaporated under reduced pressure. The residue was dissolved in 100ml of acetic acid, and treated with 3.72g of acetic anhydride (MW: 102.09, 36.45mmol). The solvent was evaporated under reduced pressure and the residue crystallized from a 1:1 ethyl acetate: hexane mixture to afford an off white solid. Yield: 6.76-g, 83%. MS: 269.4 (M+H)⁺, 267.3, (M-H)⁻. Method ESI⁺, ESI⁻.

Step 5: 4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidine-1-carboxylic acid benzylester:

[0047] A suspension of 22.72g 1-oxa-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester (WO9803507) (MW: 247.29, 92mmol), 21.45g N-[(5S)-{3-(3-fluoro-4-hydroxy-phenyl)}-2-oxo-oxazolidin-5-ylmethyl]-acetamide (MW: 268.246, 80mmol) and 16.58g potassium carbonate (MW: 138.20, 120mmol) in 150ml dimethylformamide was stirred at 100°C for 7 hours. The reaction was monitored by TLC (dichloromethane / methanol 9:1). The dimethylformamide was evaporated under reduced pressure and the residue was dissolved in 600ml of a 9:1 dichloromethane /methanol mixture. The organic layer was washed with 400ml water and 400ml brine. The organic layer was dried over magnesium sulfate, filtered, and the filtrate diluted with 250ml ethyl acetate. The mixture was concentrated under reduced pressure to a final volume of 400ml. The slurry was stirred at room temperature over night. The crystals were filtered and washed successively with 150ml ethyl acetate and 100ml pentane. Yield: 31.65 g, 76.7%. MS: 516.8 (M+H)⁺, Method ESI⁺.

Step 6: N- [(5S)-3[3-fluoro-4-(4-hydroxy-piperidin-4-yl-methoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-acetamide:


[0048] A suspension of 31g 4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenoxy-methyl}-4-hydroxy-piperidine-1-carboxylic acid benzylester (MW: 515.54 60.13mmol) and 2.5 g of palladium 10% on activated carbon in 310ml methanol and 150ml ethyl acetate was stirred under hydrogen for 4 hrs. The reaction was monitored by TLC (ethyl acetate). The reaction slurry was diluted with 300ml methanol, warmed to 40 °C, and the catalyst filtered off using a glass fibre filter paper. The filtrate was concentrated to 150ml, diluted with 300ml ethyl acetate and concentrated again to 200ml. 200ml of diethyl ether were added, and the suspension was cooled to 0°C under stirring. The solid was collected and dried. Yield: 21.6-g, 94.3%. MS: 382.6 (M+H)⁺, Method ESI⁺.

Step7: 7-(4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl)-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8] naphthyridine-3-carboxylic acid:

[0049] A suspension of 71mg 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-[1,8]naphthyridine-3-carboxylic acid (MW: 282.66, 0.25mmol), 95mg N-[(5S)-3[3-fluoro-4-(4-hydroxy-piperidin-4-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-acetamide (MW: 381.40, 0.25mmol) 102mg triethylamine (MW: 101.19, 1.0mmol) and 81mg trimethylchlorosilan (MW: 108.64, 0.75mmol) in 1ml N-methylpyrrolidin-2-one was heated at 80°C under stirring for 5 hours. The reaction was monitored by TLC (dichloromethane: methanol 9:1). The N-methyl-pyrrolidin-2-one was evaporated, the residue dissolved in 20ml of a 9:1 dichloromethane : methanol mixture, and the solution washed sequentially with 10ml of 0.1 N aqueous hydrochloric acid and 20ml brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate evaporated. The residue was dissolved in 10ml of a 9:1 dichloromethane: methanol mixture and diluted with 20ml ethyl acetate. The precipitated solid was collected to afford an off white solid. A second crop is obtained by concentration under reduced pressure of the mother liquor. Yield: 100mg, 64%. MS: 628.8 (M+H)⁺, 626.8. (M-H)⁻ Method ESI⁺, ESI⁻

Example 2: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid

[0050]



Step 1: 7-[4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(bis-benzyloxy-phosphoryloxy)-piperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine -3-carboxylic acid:

[0051] A suspension of 125mg 7-(4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl)-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid (MW: 627.60,


0.2mmol) and 42mg tetrazole (MW:70.05, 0.6mmol) in 1ml dichloromethane was treated with 138mg of dibenzyl N,N-diisopropylphosphoramidite (MW: 345.42, 0.4mmol). The original suspension slowly cleared. The solution was stirred at room temperature for two hours and monitored by TLC. (dichloromethane/methanol 9:1). The reaction mixture was cooled to 0°C and treated with a 0.6ml of a 0.5M m-chloroperbenzoic acid solution in dichloromethane. The mixture was stirred for two hours at room temperature and diluted with 20ml dichloromethane. The organic layer was washed successively with 20ml of a saturated aqueous sodium bicarbonate solution and 20ml of brine and dried over magnesium sulfate. The slurry was filtered and the filtrate evaporated under reduced pressure. The residue was purified by chromatography over silica using a 9/1 dichloromethane/methanol mixture as eluent to afford an off white solid. Yield: 158mg, 89%. MS: 889.3 (M+H)⁺, 887.0 (M-H)⁻ Method ESI⁺, ESI⁻.

Step 2: 7-(4-{4-[(5S)-(5-Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-phosphonoxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid:

[0052] A suspension of 158mg 7-[4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(bis-benzyloxy-phosphoryloxy)-piperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8] naphthyridine-3-carboxylic acid (MW: 887.84, 0.177mmol) and 20mg of palladium hydroxide 20% on activated carbon in 20ml of a 6/3/1 dichloromethane/methanol/ water mixture was stirred at room temperature under hydrogen for three hours. The catalyst was filtered off using a glass fibre filter paper. The solvents were evaporated under reduced pressure and the residue dissolved in 10ml methanol. The solution was diluted with 20ml water while a white solid precipitated. The solid was collected and dried. Yield: 85mg, 68%. MS: 709.0 (M+H)⁺, 706.5 (M-H)⁻ Method ESI⁺, ESI⁻.

Example 3: 7-[4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(2,6-diamino-hexanoyloxy)-piperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid

[0053]



Step 1: 4-{4-[(5S)-(5-Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester:

[0054] In analogy of example 1 step 5 by reacting 3.83g 1-oxa-6-aza-spiro[2.5]octane-6-carboxylic acid tert-butyl ester (WO0204462) (MW: 213.28 18mmol), 4.02g N-[(5S)-{3-(3-fluoro-4-hydroxy-phenyl)}-2-oxo-oxazolidin-5-ylmethyl]-acetamide (MW: 268.246, 15mmol) and 3.1g potassium carbonate (MW: 138.20, 22.5mmol) in 30ml dimethylformamide. Yield: 4.89-g, 67%. MS: 482.6 (M+H)⁺, Method ESI⁺.

Step 2: 4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(2,6-bis-benzyloxycarbonylamino-hexanoyloxy)-piperidine-1-carboxylic acid tert-butyl ester:

[0055] A suspension of 96mg of 4-{4-[5-(5S)-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (MW: 481.52, 0.2mmol), 195mg of Z-Lys (Z)-OH (MW: 414.46, 0.4mmol) and 49mg of 4-dimethylaminopyridine (MW: 122.17, 0.4mmol) in 2ml dichloromethane was treated under stirring at room temperature with 115mg N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimid hydrochloride (MW: 191.70,

0.6mmol). The reaction mixture was stirred over night. The mixture was diluted with 20ml ethyl acetate and the organic layer washed successively with 10ml 1 N aqueous hydrochloric acid, 20ml water and 20ml brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate evaporated to dryness. The residue was purified by chromatography on silica, using a 9/1 dichloromethane/ methanol mixture as eluent to leave a colorless sticky oil. Yield: 150mg, 88%. MS: 878.8 (M+H)⁺, Method ESI⁺.

Step 3: 2,6-Bis-benzyloxycarbonylamino-hexanoic acid 4-{4-[(5S)-5-(acetyl-amino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-piperidin-4-yl ester hydrochloride:

[0056] 200mg of 4-{4-[5-(5S)-(acetyl-amino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(2,6-bis-benzyloxycarbonylamino-hexanoyloxy)-piperidine-1-carboxylic acid tert-butyl ester (MW: 977.97, 0.22mmol) were dissolved in 4ml of a 1.25M dry hydrochloric acid in methanol. The reaction was stirred at 40°C for two hours, and the solvent removed by distillation under reduced pressure to leave a off white solid. Yield: 178mg, quantitative. MS: 778.8 (M+H)⁺, Method ESI⁺.

Step 4: 7-[4-{4-[(5S)-5-(Acetyl-amino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(2,6-bis-benzyloxycarbonylamino-hexanoyloxy)-piperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid:


[0057] In analogy to example 1 step 7, with 62mg 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-[1,8]naphthyridine-3-carboxylic acid (MW:282.66, 0.25mmol), 178mg 2,6-bis-benzyloxycarbonylamino-hexanoic acid 4-{4-[5-(5S)-(acetyl-amino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-piperidin-4-yl ester hydrochloride (MW: 814.31, 0.22mmol), 90mg triethylamine (MW: 101.19, 0.88mmol) and 48mg trimethylchlorsilan (MW: 108.64, 0.44mmol) in 1ml N-methyl-pyrrolidin-2-one. Yield: 94mg, 42%. MS: 1025.3 (M+H)⁺, Method ESI⁺.

Step 5: 7-[4-{4-[(5S)-5-(Acetyl-amino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(2,6-diamino-hexanoyloxy)-piperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid:

[0058] A suspension of 94mg 7-[4-{4-[(5S)-5-(acetyl-amino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(2,6-bis-benzyloxycarbonylamino-hexanoyloxy)-piperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid (MW: 1024.05, 0.091mmol) and 20mg of palladium hydroxide 20% on activated carbon in 20ml of a 6/3/1 dichloromethane/methanol/water mixture was stirred at room temperature under hydrogen for four hours. The catalyst was filtered off using a glass fibre filter paper. The solvents were evaporated under reduced pressure and the residue dissolved in 10ml methanol. The solution was diluted with 20ml water while a white solid precipitated. The solid was collected and dried. Yield: 29mg, 43%. MS: 757.0 (M+H)⁺, 755.2 Method ESI⁺, ESI⁻.

Example 4: Succinic acid mono-[4-{4-[(5S)-5-(acetyl-amino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-1-(6-carboxy-8-cyclopropyl-3-fluoro-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl)-piperidin-4-yl] ester

[0059]



Step 1: Succinic acid 4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-1-tert-butoxy-carbonyl-piperidin-4-yl ester benzyl ester:

[0060] In analogy of example 3 step 2 with 825mg 4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (MW: 481.52, 1.71mmol), 1.07g of succinic acid monobenzyl ester (MW: 208.21, 5.14mmol) and 0.63g of 4-dimethylaminopyridine (MW: 122.17, 5.1mmol) in 10ml dichloromethane was treated under stirring at room temperature with 1.3g N-(3-dimethylaminopropyl)-N'-ethyl-carbod-iimid HCl (MW: 191.70, 6.8mmol). Yield: 820mg, 70%. MS: 673.3 (M+H)⁺, Method ESI⁺.

Step 2: Succinic acid 4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-piperidin-4-yl ester benzyl ester:

[0061] 820mg of succinic acid 4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-1-tert-butoxycarbonyl-piperidin-4-yl ester benzyl ester (MW: 671.72, 1.23mmol) were dissolved in 4ml of trifluoro acetic acid. The reaction mixture was stirred at room temperature for one hour. The solvent was evaporated, the residue dissolved in 30ml of a 9/1 dichloromethane/methanol mixture and the organic layer washed successively with 30ml of a saturated aqueous sodium bicarbonate solution and 30ml of brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate evaporated under reduced pressure. The residue was purified by chromatography over silica, using a 95/5 dichloromethane/ methanol mixture with 2% triethylamine as eluent. Yield: 420mg, 60%. MS: 572.7 (M+H)⁺, Method ESI⁺.

Step 3: Succinic acid 4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-1-(6-carboxy-8-cyclopropyl-3-fluoro-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl)-piperidin-4-yl ester benzyl ester:


[0062] In analogy to example 1 step 7, with 113mg 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-[1,8]naphthyridine-3-carboxylic acid (MW:282.66, 0.4mmol), 230mg succinic acid 4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-piperidin-4-yl ester benzyl ester (MW: 571.60, 0.4mmol), 161mg triethylamine (MW: 101.19, 1.6mmol) and 87mg trimethylchlorosilan (MW: 108.64, 0.8mmol) in 2ml N-methyl-pyrrolidin-2-one. Yield: 25mg, 7.6%. MS: 819 (M+H)⁺, 817.8, Method ESI⁺, ESI⁻.

Step 4: Succinic acid mono-[4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-1-(6-carboxy-8-cyclopropyl-3-fluoro-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl)-piperidin-4-yl] ester:

[0063] In analogy to example 3 step 5 with 22mg succinic acid 4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-1-(6-carboxy-8-cyclopropyl-3-fluoro-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl)-piperidin-4-yl ester benzyl ester (MW: 817.80, 0.026mmol) and 2mg of palladium hydroxide 20% on activated carbon in 20ml of a 1/1 tetrahydrofuran/ methanol mixture. Yield: 16mg, 81%. MS: 729 (M+H)⁺, 727 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 5: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

[0064]




[0065] A solution of 60g N-[[[(5S)-3[3-fluoro-4-(4-hydroxy-piperidin-4-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-acetamide. (C₁₈H₂₄FN₃O₅, MW: 381.40 0.157 mole) and 26.87ml of ethyl diisopropylamine (MW: 129.25, 0.157 mole) in 300ml N-methyl-pyrrolidin-2-one was treated with 67.81g (7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-

3-quinolinecarboxylic acid-boron diacetate complex (MW:410.57, 0.165 mole) and the mixture was stirred at 80°C for 5 hours. The N-methyl-pyrrolidin-2-one was evaporated under reduced pressure and residue was dissolved in 300ml of methanol. Anhydrous hydrogen chloride was bubbled through the solution at 10 °C for 30 minutes. The solution was stirred at room temperature while a yellow solid precipitated. The conversion of the boron complex to the free acid was monitored by HPLC. The mixture was diluted with 300ml ethyl acetate. The solid was filtered and washed with 100ml of 8/2 ethyl acetate/methanol and 100ml of ethyl acetate. The yellow solid was dried to leave 86.4 g of a yellow solid. The solid was dissolved in 200ml dimethylsulfoxide at 40 °C, and the yellow solution was added under stirring to 1000ml water. The yellow solid was collected, washed with water and dried. Yield: 73g, 74.5%. MS: 627.8 (M+H)⁺, 625.8 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 6: 7-[4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(bis-benzyloxy-phosphoryloxy)-piperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid


[0066]



[0067] A suspension of 35g 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (MW: 626.61, 55.85mmol) and 6.45g tetrazole (MW: 70.05, 92.15mmol) in 700ml dichloromethane was treated at room temperature under stirring with a solution of 31.8g dibenzyl-diisopropylphosphoramidite (MW: 345.42, 92.15mmol) in 20ml dichloromethane. The reaction was monitored by TLC (dichloromethane/methanol 9:1). The reaction was stirred for one hour and the mixture was washed at 0°C with 200ml 1N aqueous hydrochloric acid and 100ml of a saturated sodium bicarbonate solution. The water layer were backwashed with 200ml dichloromethane. The combined organic layer were concentrated to 500ml and treated at roomtemperature with 13.2ml of a 70 % ter-butyl hydroperoxid solution in water (MW:90.12, 95mmol). The reaction was stirred for 30 min, diluted with 500ml dichloromethane and the organic layer washed with 200ml 1N aqueous hydrochloric acid and with 300ml brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate evaporated under reduced pressure. The residue was dissolved in 400ml dichloromethane and diluted with 400ml N-hexane. The mixture was concentrated (300-mbar, 40°C bath temperature) to a volume of 400ml. The sticky oil was decanted and dissolved in 400ml of refluxing methanol. The solution was concentrated to 300ml under reduced pressure and stirred over night at RT. The slurry was cooled to 0°C and the solid collected. Yield: 27.60g, 55.6%. MS: 888.3 (M+H)⁺, 885.8 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 7: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

[0068]




[0069] 27g 7-[4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-(bis-benzyloxy-phosphoryloxy)-piperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (MW: 886.85, 30.44mmol) were suspended in 600ml acetonitrile and treated with 53ml of a 33% solution of anhydrous hydrobromic acid in acetic acid. The yellow suspension was diluted with 150ml of acetic acid and was heated to 45°C. The reaction was monitored by HPLC/MS and was complete after 3 hours.

[0070] The sticky suspension was added to 1.5 L of water under stirring. The off white crystals were collected, washed with 300ml water, 150ml ethanol and 150ml ether. The solid was suspended in 1.3L water and treated with 35ml (35mmol) of a 1M aqueous sodium hydroxide solution. The solid dissolved, and the brown-yellow solution was treated with 15 g of activated charcoal and filtered. The filtrate was extracted with 3 portions of 200ml of a 95/5 dichloromethane/ methanol mixture. The water layer was treated with 40ml of 1 M HCl solution and the product crystallized by stirring. The solid was collected and dried. Yield: 17.3-g, 80.4 %. MS: 609.7 (M+H)⁺, 607.8 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 8: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid


[0071]



[0072] In analogy to example 5 with 114mg N-[(5S)-3[3-fluoro-4-(4-hydroxy-piperidin-4-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-acetamide. (MW: 381.40 0.3mmol), 127mg of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid diacetylborate (Sakurai, Nobuhiro; Sano, Mitsuharu; Hirayama, Fumihiko; Kuroda, Tsuyoshi; Uemori, Satoru; Bioorg.Med.Chem.Lett.; 8; 16; 1998; 2185-2190) (MW: 423.137, 0.3mmol) and 38mg of ethyl diisopropylamine (MW: 129.25, 0.3mmol) in 1ml N-methylpyrrolidin-2-one. Yield: 137mg, 69.5 %. MS: 658.2 (M+H)⁺, 655.8 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 9: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid


[0073]



[0074] In analogy to example 5 with 114mg N-[(5S)-3[3-fluoro-4-(4-hydroxy-piperidin-4-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-yl-methyl]-acetamide. (MW: 381.40 0.3mmol), 121mg of 1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylatoboron diacetate (WO03032962) (MW: 405.15, 0.3mmol) and 77mg of ethyl diisopropylamine (MW: 129.25, 0.6mmol) in 2ml N-methyl-pyrrolidin-2-one. Yield: 117mg, 61.2 %. MS: 639.8 (M+H)⁺, 637.5 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 10: 9-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-piperidin-1-yl)-8-fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid


[0075]



[0076] A solution of 140mg of 9-10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (MW: 281.22, 0.5mmol), 191mg of N-[(5S)-3[3-fluoro-4-(4-hydroxy-piperidin-4-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-yl-methyl]-acetamide (MW: 381.40, 0.5mmol), and 129mg of ethyl diisopropylamine (MW: 129.25, 1mmol) was stirred at 80°C in 1ml of N-methyl-pyrrolidin-2-one for 24 hours. The solvent was evaporated under reduced pressure. The residue was dissolved in methanol and treated with 10ml of a 1.2 M anhydrous hydrogen chloride solution in methanol. The methanol was evaporated and the residue digested in ethyl acetate. The solid was collected and crystallized twice from a dichloromethane/ethanol mixture. Yield: 88mg, 27 %. MS: 643.7 (M+H)⁺, 641.5 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 11: 7-(3-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-3-hydroxy-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid

[0077]



Step 1: 1-Oxa-5-aza-spiro[2.4]heptane-5-carboxylic acid benzyl ester:

[0078] A solution 3-methylen-pyrrolidine-1-carboxylic acid benzyl ester (WO9624593) in 5ml of dichloromethane was treated with 2.16g sodium bicarbonate (MW: 84.01 26.28mmol) and 2.47g of 80% m-chlor-perbenzoic acid (MW: 172.57, 11.48mmol). The reaction mixture was stirred at room temperature for three hours. The reaction mixture was diluted with 20ml of a saturated aqueous sodium sulfite solution and 45ml of dichloromethane. The organic layer was successively washed with 30ml of an aqueous saturated sodium bicarbonate solution and brine. The organic layer was dried over magnesium sulfate. The residue was purified by chromatography on silica (1/1 ethyl acetate/n-hexane) to afford a off white solid. Yield: 440mg, 57 %. MS: 234.1(M+H)⁺, Method ESI⁺.

Step 2: 3-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-3-hydroxy-pyrrolidine-1-carboxylic acid benzyl ester:

[0079] A solution of 420mg of N-[(5S)-{3-(3-fluoro-4-hydroxyphenyl)}-2-oxo-oxazolidin-5-ylmethyl]-acetamide (MW: 268.246, 1.56mmol) in 2ml dimethylformamide was treated with 83mg sodium hydride. The suspension was stirred for one hour at room temperature. A solution of 440mg 1-oxa-5-aza-spiro[2.4]heptane-5-carboxylic acid benzyl ester (MW: 233.26, 1.88mmol) in 1ml DMF was added and the mixture was stirred at 70°C for three hours. The dimethylformamide was evaporated under reduced pressure and the residue was purified by chromatography over silica (95/5 dichloromethane/methanol mixture with 1% ammonia) to afford an off white powder. Yield: 630mg, 80 %. MS: 502.5 (M+H)⁺, Method ESI⁺.

Step 3: N-[(5S)-3-[3-Fluoro-4-(3-hydroxy-pyrrolidin-3-yl-methoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-acetamide:


[0080] A suspension of 660mg 3-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-3-hydroxy-pyrrolidine-1-carboxylic acid benzyl ester (MW: 501.51, 1.31mmol) and 20mg palladium 10% on activated carbon in 20ml of a 1/1 ethyl acetate / methanol mixture was stirred for twelve hours under hydrogen. The catalyst was filtered on a glass fiber filter paper and the filtrate evaporated under reduced pressure to afford a colorless oil. Yield: 400mg, 83.2 %. MS: 368.4 (M+H)⁺, Method ESI⁺.

Step 4: 7-(3-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-3-hydroxy-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid:

[0081] In analogy to example 1, step 7 with 39mg 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-[1,8]naphthyridine-3-carboxylic acid (MW: 282.66, 0.24mmol), 99mg N-[(5S)-3-[3-fluoro-4-(3-hydroxy-pyrrolidin-3-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-acetamide. (MW: 367.38, 0.24mmol) 101mg triethylamine (MW: 101.19, 1.0mmol) and 80mg trimethylchlorosilan (MW: 108.64, 0.75mmol) in 2ml N-methylpyrrolidin-2-one. Yield: 70mg, 46 %. MS: 614.7(M+H)⁺, 612.7 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 12: 7-(3-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-3-hydroxy-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid


[0082]



[0083] In analogy to example 5 with 106mg N-((5S)-3-[3-fluoro-4-(3-hydroxypyrrolidin-3-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl)-acetamide. (MW: 367.38, 0.29mmol) 119mg (7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid-boron diacetate complex (MW: 410.57, 0.29mmol) and 75mg of ethyl diisopropylamine (MW: 129.25, 0.58mmol) in 2ml N-methyl-pyrrolidin-2-one. Yield: 19mg, 11 %. MS: 613.5 (M+H)⁺, 611.5 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 13: 7-(3-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-3-hydroxy-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid


[0084]



[0085] In analogy to example 5 with 143mg N-((5S)-3-(3-fluoro-4-(3-hydroxy-pyrrolidin-3-ylmethoxy)-phenyl)-2-oxo-oxazolidin-5-ylmethyl)-acetamide (MW: 367.38, 0.39mmol), 165mg of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid diacetylborate (MW: 423.137, 0.39mmol) and 100mg of ethyl diisopropylamine (MW: 129.25, 0.78mmol) in 2ml N-methyl-pyrrolidin-2-one. Yield: 143mg, 57 %. MS: 643.7 (M+H)⁺, 641.7 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 14: 7-(3-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-3-hydroxy-pyrrolidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

[0086]




[0087] In analogy to example 5 with 48mg N-((5S)-3-[3-fluoro-4-(3-hydroxy-pyrrolidin-3-ylmethoxy)-phenyl]-2-oxo-

oxazolidin-5-ylmethyl}-acetamide (MW: 367.38, 0.13mmol), 53mg of 1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylatoboron diacetate (MW: 405.15, 0.13mmol) and 33mg of ethyl diisopropylamine (MW: 129.25, 0.26mmol) in 1ml N-methyl-pyrrolidin-2-one. Yield: 41mg, 50 %. MS: 625.8 (M+H)⁺, 623.8 (M+H)⁻, Method ESI⁺, ESI⁻.

Example 15: 9-(3-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-3-hydroxy-pyrrolidin-1-yl)-8-fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid


[0088]



[0089] In analogy to example 10 with 110mg of 9-10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (MW: 281.22, 0.39mmol), 143mg of N-{(5S)-3-[3-fluoro-4-(3-hydroxy-pyrrolidin-3-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide. (MW: 367.38, 0.39mmol), and 100mg of ethyl diisopropylamine (MW: 129.25, 0.78mmol) in 2ml of N-methyl-pyrrolidin-2-one. Yield: 103mg, 42 %. MS: 629.8 (M+H)⁺, Method ESI⁺.

Example 16: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-azepan-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

[0090]



Step 1: 4-Methylene-azepane-1-carboxylic acid tert-butyl ester:

[0091] A solution of 1g methyltriphenylphosphoniumbromide (MW: 357.22, 2.79mmol) in 20ml of tetrahydrofuran was treated at -78°C with 1.22ml of a 2.3 M n-butyl lithium solution in N-hexane (2.8mmol). The reaction mixture was stirred at -78°C for ten minutes, then at 0°C for one hour. The yellow suspension was cooled to -78°C and treated with a solution of 595mg 4-oxo-azepane-1-carboxylic acid tert-butyl ester (WO 2000044376) (MW: 213.279, 2.78mmol) in 10ml tetrahydrofuran. The reaction mixture was stirred at room temperature for one and half hour. The reaction mixture was quenched with 30ml of a saturated aqueous solution of ammonium chloride, diluted with 30ml of ethyl acetate. The organic layer was successively washed with 30ml water and 30ml brine, dried over magnesium sulfate and filtered. The filtrate was evaporated under reduced pressure and the residue purified by chromatography over silica. (cyclohexane: ethyl acetate 1:1). Yield: 487mg, 83%. NMR (CDCl₃): 1.35 ppm (s, 9 H, tert-but.); 1.6 ppm (m, 2H, -CH₂-); 2.14 ppm (m, 2H), 2.33 ppm (m, 2H); 3.29 ppm (m, 4H, N-CH₂); 4.67 ppm (m, 2H, vinyl-CH₂).

Step 2: 1-Oxa-6-aza-spiro[2.6]nonane-6-carboxylic acid tert-butyl ester:

[0092] In analogy to example 11 step 1 with 4-methylene-azepane-1-carboxylic acid tert-butyl ester (MW:211.307, 1.73mmol), 1.16g sodium bicarbonate (MW: 84.01 13.8mmol) and 1.36g of 80% m-chloroperbenzoic acid (MW172.57,

6.05mmol) in 5ml of dichloromethane. Yield: 250mg, 63 %. MS: 228.8 (M+H)⁺, 127.8 (M-(CH₃)₃COCO) method ESI⁺.

Step 3: 4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-azepane-1-carboxylic acid tert-butyl ester:

[0093] In analogy to example 1 step 5 with 247mg of 1-oxa-6-aza-spiro[2.6]nonane-6-carboxylic acid tert-butyl ester. (MW: 227.31 1.08mmol), 296mg N-[(5S)-{3-(3-fluoro-4-hydroxyphenyl)}-2-oxo-oxazolidin-5-ylmethyl]-acetamide (MW: 268.246, 80mmol) and 228mg potassium carbonate (MW: 138.20, 1.65mmol) in 150ml dimethylformamide. Yield: 334mg, 62 %. MS: 496.8 (M+H)⁺, 440.8 (M-C(CH₃)₃H)⁺, Method ESI⁺.

Step 4: N-[(5S)-3-[3-Fluoro-4-(4-hydroxy-azepan-4-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-acetamide:


[0094] A solution of 334mg 4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-azepane-1-carboxylic acid tert-butyl ester (MW:495.55, 0.674mmol) in 3ml of a 1.25 M anhydrous hydrogen chloride solution in methanol was stirred at 35°C for four hours. The solvent was evaporated under reduced pressure. The residue was dissolved in 4ml water and the water layer neutralized to pH 7 with a saturated sodium bicarbonate solution. The water was evaporated and the residue dissolved in 30ml of a 9/1 dichloromethane/methanol mixture. The insoluble salt were filtered and the filtrate evaporated to dryness to afford off white solid. Yield 266mg, quant. MS: 395.8 (M+H)⁺, 440.6 (M+HCOO)⁻, Method ESI⁺, ESI⁻.

Step 5: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-azepan-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid:

[0095] In analogy to example 5 with 150mg N-[(5S)-3-[3-fluoro-4-(4-hydroxy-azepan-4-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-acetamide (MW: 395.43) and 98mg of ethyl diisopropylamine (MW: 129.25, 0.758mmol), 163mg (7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid-boron diacetate complex (MW:410.57, 0.397mmol) in 2ml N-methyl-pyrrolidin-2-one. Yield: 70mg, 28.8 %. MS: 641.7 (M+H)⁺, method ESI⁺.

Example 17: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-hydroxy-azepan-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid

[0096]



[0097] In analogy to example 1 step 7 with 98mg 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-[1,8]naphthyridine-3-carboxylic acid (MW: 282.66, 0.348mmol), 138mg N-[(5S)-3-[3-fluoro-4-(4-hydroxy-azepan-4-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-acetamide (MW: 395.43, 0.348mmol), 140mg triethylamine (MW: 101.19, 1.39mmol) and 113mg trimethylchlorosilane (MW: 108.64, 1.04mmol) in 1ml N-methylpyrrolidin-2-one. Yield: 150mg, 77 %. MS: 642.7 (M+H)⁺, 640.7 (M+H)⁻, Method ESI⁺, ESI⁻.


Example 18: sodium salt of 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxy-methyl}-4-phosphonoxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

[0098] 183 g of the compound of example 7 were dissolved in 400 mL dry DMSO at room temperature. Then the solution was treated with 60 g Fullers earth and filtered off. The remaining solid was washed with 50 mL dry DMSO. The combined filtrates were mixed with another 50 mL of dry DMSO and 2000 mL of dry acetone under nitrogen. To this solution a solution of 47.1 g sodium-2-ethylhexanoate (97% in ethyl acetate, i.e. 250 mL) was added drop wise at room

temperature. The resulting suspension was then stirred for 1 h, followed by the addition of 2750 mL ethyl acetate at room temperature. The resulting suspension was stirred for another hour and the resulting crystals were collected by filtration, washing the solid with ethyl acetate (10 x 500 ml) to remove the DMSO and then dried in vacuo. If there is still amounts of DMSO and/or ethyl acetate remaining, then the solid was slurred with acetone / water (99:1) for 24 h. The mixture was then filtered, washed with acetone / water (99:1) (2 x 500 ml) and then allowed to suck dry on the filter for 12 h. The solid was then dried in vacuo. Yield: 90%.

Example 19: Formation of building blocks via a Sonogashira reaction - 4-{4-[5S-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenylethynyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester.

[0099]



Step 1: (4-Bromo-3-Fluoro-phenyl)-carbamic acid benzyl ester.

[0100] Sodium hydrogen carbonate (27.63 g, 0,329 mol, 1,25eq) and a saturated solution of sodium hydrogen carbonate (333 ml) were added to a stirred solution of 4-bromo-3-fluoroaniline (50.0 g, 0,263 mol, 1eq) in acetone (660 ml). The resulting mixture was cooled to 15°C and benzyl chloroformate (39 ml, 0,276 mol, 1,05eq) was added gradually, taking care that the reaction temperature did not exceed 22°C. The mixture was stirred over 90 mins at room temperature and the acetone was removed under vacuum. The aqueous layer was then extracted with ethyl acetate (3 x 150 ml). The combined organic layers were then washed with a saturated sodium chloride solution, and dried over MgSO₄. After filtration, the solvent was removed, and n-hexane added. The mixture was stirred during 30min at room temperature, the crystals were filtrated and washed with hexane to give the first crop of solid. The filtrate was evaporated, and the solid mixed with heptane at 0°C and stirred during 30min. The product was again filtered, to give the second crop of solid. The two crops were then combined, to give the product (85,3g, quantitative) as of solid.

Step 2: (5R) 3-(4-Bromo-3-Fluoro-phenyl)-5-hydroxymethyl oxazolidin-2-one

[0101] Butyl lithium (2.3M in n-hexanes, 118,3 ml, 0,272 mol, 1,06eq) was added at -30°C to anhydrous tert-butanol (25.0 g, 0,53 mol, 2,07eq) in anhydrous THF (170 ml), under nitrogen. The mixture was stirred for 30min at -30°C, and was then allowed to warm slowly to 0°C. After 30min at 0°C, the (4-bromo-3-fluoro-phenyl)-carbamic acid benzyl ester (83 g, 0,256 mol, 1eq) was added portionwise, keeping the temperature cold, and the mixture was stirred for an additional 30min at 0°C. To this ice cold mixture, R(-)-glycidyl butyrate (39.7 ml, 0,288 mol, 1,12eq) were added and the mixture allowed to come gradually to room temperature. The mixture was extracted with saturated sodium chloride solution and the organic phase was dried over MgSO₄, filtrated and evaporated. The product was obtained after recrystallisation of the crude product with ethyl acetate, to give (64,1g , 86.4%).

Step 3: Methanesulfonic acid 3-(4-Bromo-3-Fluoro-phenyl)-2-oxo-oxazolidin-(5R)-ylemthyl ester.

[0102] Methansulfonyl chloride (27.4 ml, 0,354 mol, 1.9 eq) was added to an ice-cold solution of the (5R) 3-(4-Bromo-3-Fluoro-phenyl)-5-hydroxymethyl oxazolidin-2-one (54.0 g, 0,186 mol, 1eq) and triethylamine (51.8 ml, 0,372 mol, 2eq) in anhydrous DCM (420 ml) at 0°C. The resulting solution was allowed to come to room temperature, and then stirred over 3 hours. The mixture was then washed with 10% sodium hydrogen carbonate solution giving a precipitate. The solid was filtered, The washed with DCM, and the filtrate and washings dried over MgSO₄. After filtering, the solvent

was removed, and the resulting solid was slurried with diethyl ether. The solid was then filtered, washed with ice cold diethyl ether and dried to give the product (68,5 g, quantitative). ,

Step 4: (5R)- Azidomethyl-3-(4-Bromo-3-Fluoro-phenyl) oxazolidin-2-one

[0103] A suspension of the Methanesulfonic acid 3-(4-Bromo-3-Fluoro-phenyl)-2-oxo-oxazolidin-(5R)-ylemthyl ester (68.5 g, 0.186 mol, 1eq), tetrabutyl ammonium iodide (0.686 g, 0.00186 mol, 0.01eq) and sodium azide (24.57g, 0.378 mol, 2.03eq) in anhydrous DMF (500 ml) was stirred 80°C under nitrogen over night. The reaction was cooled, the DMF evaporated and the residue dissolved in ethyl acetate, washed with water and saturated sodium chloride and dried over MgSO₄. After filtering, the filtrate was evaporated to give the product (58.6 g, quantitative) as a white solid.

Step 5: (5R)- Aminomethyl-3-(4-Bromo-3-Fluoro-phenyl) oxazolidin-2-one.

[0104] A mixture of the (5R)- Azidomethyl-3-(4-Bromo-3-Fluorophenyl) oxazolidin-2-one (10.5 g, 33.3 mmol, 1 eq), triphenylphosphine (12.6 g, 48 mmol, 1.44 eq) and water (7.8 ml, 433 mmol, 13eq) in THF (180 ml) were stirred at 80°C. Once the reaction was finished, it was cooled and then the solvents were removed under vacuum. The residue was purified by chromatography (ethyl acetate first to remove the triphenylphosphine derivatives and then with dichloromethane/methanol 9/1) to give the product (9.63 g, quantitative) as a white solid.

Step 6: (5S)-N-[(4-bromo-3-Fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide

[0105] To the (5R)- Aminomethyl-3-(4-Bromo-3-Fluoro-phenyl) oxazolidin-2-one (9.63 g , 33.3 mmol, 1eq) was added acetic acid (9 ml, 156 mmol, 4.68eq) and acetic anhydride (9 ml, 95.3 mmol, 2.86eq). The suspension was stirred at room temperature for 1h and then the solvent was removed under high vacuum, to give the product (11.03 g, quantitative) as a beige solid.

Step 7: 4-oxo-piperidine-1-carboxylic acid tert-butyl ester.

[0106] A solution of BOC₂O (6.02 g, 27.6 mmol, 1.1 eq) in dioxane (25ml) was added to 4-Piperidone hydrochloride hydrate (3,9 g, 25.4 mmol, 1eq) in water/dioxane (50 ml, 1/1). The reaction was exothermic during the addition, and after the addition was finished the reaction was stirred for 4h at room temperature. The dioxane was evaporated and the resulting residue was extracted in ethyl acetate and then dried over MgSO₄. After filtering, the filtrate was evaporated down to give the product (5.06 g, quantitative) as a white solid

Step 8: 4-Hydroxy-4-trimethylsilanylethynyl piperidine-1-carboxylic acid tert-butyl ester.

[0107] n-Butyl lithium (2.3M solution in n-hexanes, 16.0 ml, 36.8 mmol, 1.1eq) was added to a solution of TMS-alkyne (6.03 ml, 42.4 mmol, 1.26eq) in THF (124 ml) at -78°C under nitrogen. The resulting mixture was stirred at -78°C for a further 30min, and then a solution of 4-oxo-piperidine-1-carboxylic acid tert-butyl ester (6.7 g, 33.6 mmol, 1eq) in THF (30mL) was added at -78°C. The reaction mixture was stirred 15 minutes at 78°C, and then was allowed to warmed up gradually to room temperature. After 30 min, adding 10% sodium hydrogen sulfate quenched the reaction. The two phases were separated and the aqueous layer was back extracted with ethyl acetate. The combined organic layers were washed with brine and dried over magnesium sulfate. After concentration, the pale yellow residue (7 g, 70%) was found pure enough to be carried on without further purification.

Step 9: 4-Ethynyl-4-Hydroxy-piperidine-1-carboxylic acid tert-butyl ester.

[0108] A mixture of the 4-Hydroxy-4-trimethylsilanylethynyl piperidine-1- carboxylic acid tert-butyl ester (7 g, 23.5 mmol, 1eq) and potassium carbonate (1.0 g, 7.25 mmol, 0.3eq) in MeOH (30ml) were stirred for 6 h at room temperature. After this time, the solvent was removed under reduced pressure and the residue suspended in diethyl ether. The suspension was washed with saturated ammonium chloride and water and dried over MgSO₄. After filtering, the filtrate was evaporated to give the product (4.5 g, 86%) as a white solid.

Step 10: 4-{4-[5S-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenylethynyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester.


[0109] PdCl₂(P(C₆H₅)₃)₂ (297 mg, 0.422 mmol, 0.1 eq) and 148mg of copper (I) iodide (160 mg, 0.78 mmol, 0.2 eq) were stirred at RT, under argon. Then the (5S)-N-[(4-bromo-3-Fluorophenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide

(1.40 g, 4.22 mmol, 1 eq), 4-Ethynyl-4-Hydroxy-piperidine-1-carboxylic acid tert-butyl ester (1.24 g, 5.5 mmol, 1.3 eq) in anhydrous DMF (20 ml) and diisopropylamine (10 ml) were added. The mixture was stirred at RT during 30min. As the reaction didn't start, the mixture was heated at 50°C during one night under stirring. Water and diethyl ether were added, the two layers separated, and the water layer was back extracted with diethyl ether. The combined organic extracts were then washed with saturated sodium chloride solution and dried over MgSO₄. After filtering, the filtrate was evaporated and the residue was purified by chromatography (first with ethyl acetate - in order to eliminate the triphenylphosphine residues and then with Dichloromethane/MeOH) to give the product (1.55g, 77%) as a gray solid

Example 20: Formation of building blocks via triple bond reduction

4-(2-{4-[5S-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl}-ethyl)-4-hydroxy-piperidine-1-carboxylic acid tert butyl ester

[0110]




[0111] 10% Pd/C (100mg) was added a stirred solution of the 4-{4-[5S-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenylethynyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (example 19)(0.95 g, 2 mmol, 1eq) in methanol/ethyl acetate (20 ml 1/1). The mixture was then hydrogenated using a balloon of hydrogen. When the reaction went to completion, the 10% Pd/C was then removed by filtration over celite and the solid then washed with methanol/ethyl acetate (2 x 10 ml 1/1). The filtrate and washings were evaporated down to give a white solid (0.96 g, quantitative) that was found pure enough to be carried on without further purification.

General procedure for the removal of the t-butyl protecting groups

[0112] Hydrogen chloride (1.25 M solution in methanol, 4.0 eq) was added to the amine (1eq) at room temperature. The mixture is either stirred at room temperature or heated at 40°C until finished, cooled and then the pH was adjusted to pH10 using saturated sodium hydrogen carbonate solution. The resulting mixture was evaporated and dissolved again with dichloromethane/methanol 9/1. The flask containing the mixture was then placed in an ultrasound bath, sonicated for 5 mins and then filtered. The filtrate was then evaporated to give the product that was then used without further purification, to couple to the quinolone moieties.

Example 21: 7-(4-{4-[5S-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenylethynyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid


[0113]



[0114] This was prepared by using the general deprotection method for the tert-butyl ester above to give the amine. The resulting amine was then coupled to the required quinoline using the method described in example 5. This gave the required product in 8% yield over two steps.

Example 22: 7-(4-(4-[5S-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenylethynyl)-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]-naphthyridine-3-carboxylic acid


[0115]



[0116] This was prepared by using the general deprotection method for the tert-butyl ester above to give the amine. The resulting amine was then coupled to the required quinoline using the method described in example 1 - step 7. This gave the required product in 15 % yield over two steps.

Example 23: 7-(4-(2-(4-[5S-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl)-ethyl)-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid


[0117]



[0118] This was prepared by using the general deprotection method for the tert-butyl ester above to give the amine. The resulting amine was then coupled to the required quinoline using the method described in example 5. This gave the required product in 10% yield over two steps.

Claims

1. Compounds of formula (I)



wherein

A is an alkylene group, an alkenylene group, an alkynylene group, a heteroalkylene group, a cycloalkylene group, a heterocycloalkylene group, an arylene group or a heteroarylene group all of which groups may be substituted;

Q is CR⁴;

X is CR⁷ or N;

Y is CR⁶ or N;

n is 1, 2 or 3;

m is 1, 2 or 3;


R¹ is H, F, Cl, Br, I, OH, NH₂, an alkyl group or a heteroalkyl group;

R² is H, F or Cl;

R³ is H, an alkyl group, an alkenyl group, an alkynyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalkyl group; all of which groups may be substituted with one, two or more halogen atoms or amino groups;

R⁴ is hydroxy, a group of formula OPO₃R⁹₂ or OSO₃R¹⁰ or a heteroalkyl group carrying at least one OH, NH₂, SO₃R¹⁰, PO₃R⁹₂ or COOH group or an ester of a naturally occurring amino acid or a derivative thereof, wherein the groups R⁹ independently of each other are H, alkyl, cycloalkyl, aryl or aralkyl and wherein R¹⁰ is H, alkyl, cycloalkyl, aryl or aralkyl;

R⁵ is selected from the following groups:



R⁶ is H, F, Cl or OMe;

R⁷ is H, F, Cl, OH, NH₂, a substituted or unsubstituted alkyl group or a substituted or unsubstituted heteroalkyl group, or

R³ and R⁷ can be linked via an alkylene, an alkenylene or a heteroalkylene group or be a part of a cycloalkylene or heterocycloalkylene group; in case R³ is no H and R⁷ is no H, F, OH, NH₂ or Cl; and

R⁸ is a C₁₋₆ heteroalkyl, a heteroarylalkyl, a heteroalkylaryl or a heteroalkylheteroaryl group; or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

2. Compounds according to claim 1, wherein R¹ is H.

3. Compounds according to claim 1 or 2, wherein R² is F or H.

4. Compounds according to any one of claims 1 to 3, wherein R³ is an ethyl, a 2-propyl, a C₃-C₆ cycloalkyl, a phenyl or a pyridyl group; all of which may be substituted with one, two, three or more fluorine atoms or amino groups.

5. Compounds according to any one of claims 1 to 4, wherein R³ is a cyclopropyl group.

6. Compounds according to any one of claims 1 to 3, wherein R⁷ and R³ together form a bridge of the formula -O-CH₂-N(Me)- or -O-CH₂-CH(Me)-, wherein the preferred stereochemistry at the chiral center is the one giving the (S) configuration in the final compound.


7. Compounds according to any one of claims 1 to 5, wherein R⁷ is H, F, Cl or a methoxy group which may be substituted by one, two or three fluorine atoms.

8. Compounds according to any one of claims 1 to 5, wherein X is N or CH.

9. Compounds according to any one of claims 1 to 8, wherein R⁴ is hydroxy or a group of formula OSO₃H, OPO₃H₂, OCH₂OPO₃H₂, OCOCH₂CH₂COOH or an ester of a naturally occurring amino acid or a derivative thereof.

10. Compounds according to any one of claims 1 to 9, wherein R⁸ is a group of the formula -CH₂NHCOCH=CHAr₁, -CH₂OHeteroaryl, -CH₂NHSO₂Me, -CH₂NHCOOMe, -CH₂NHCOMe, -CH₂NHCS₂Me, -CH₂NHCSMe, -CH₂NHCSNH₂, -CH₂NHCSOMe or -NHCOMe.

11. Compounds according to any one of claims 1 to 10, wherein R⁵ has the following structure:




12. Compounds according to any one of claims 1 to 11, wherein Y is CH or N.


13. Compounds according to any one of claims 1 to 12, wherein A is C₁₋₆ alkylene, C₂₋₆ alkenylene, C₂₋₆ alkynylene, C₁₋₆ heteroalkylene, cyclopropylene, epoxide, aziridine, thioepoxide, lactame or lactone, all of which groups may be substituted.
14. Compounds according to any one of claims 1 to 12, wherein A is a group of formula -CH₂CH₂-, -OCH₂-, -OCH₂CH₂-, -SCH₂-, -SCH₂CH₂-, -CH=CH-, -C=C-, -CH(OH)CH(OH)- or -CH(NH₂)CH(OH)-.
15. A mono, di or tri sodium salt of a compound of formula (I) according to any one of claims 1 to 14, or mixtures thereof, especially a mono, di or tri sodium salt of a compound of formula (I), wherein R⁴ is OPO₃H₂ or OSO₃H or mixtures thereof.
16. Pharmaceutical compositions containing a compound according to any one of Claims 1 to 15 and optionally carriers and/or adjuvants and/or diluents.
17. Use of a compound or a pharmaceutical composition according to any one of Claims 1 to 16 for the manufacture of medicaments for the treatment of bacterial infections.

Patentansprüche

1. Verbindungen der Formel (I)



wobei A eine Alkylen-Gruppe, eine Alkenylen-Gruppe, eine Alkynylen-Gruppe, eine Heteroalkylen-Gruppe, eine Cycloalkylen-Gruppe, eine Heterocycloalkylen-Gruppe, eine Arylen-Gruppe oder eine Heteroarylen-Gruppe darstellt, welche Gruppen alle substituiert sein können;
 Q den Rest CR⁴ darstellt;
 X den Rest CR⁷ oder N darstellt;
 Y den Rest CR⁶ oder N darstellt;
 n den Wert 1, 2, oder 3 annimmt;
 m den Wert 1, 2, oder 3 annimmt;
 R¹ H, F, Cl, Br, I, OH, NH₂, eine Alkyl-Gruppe oder eine Heteroalkyl-Gruppe darstellt;
 R² H, F oder Cl darstellt;
 R³ H, eine Alkyl-Gruppe, eine Alkenyl-Gruppe, eine Alkynyl-Gruppe, eine Heteroalkyl-Gruppe, eine Cycloalkyl-Gruppe, eine Heterocycloalkyl-Gruppe, eine Aryl-Gruppe, eine Heteroaryl-Gruppe, eine Alkylaryl-Gruppe oder eine Heteroarylalkyl-Gruppe darstellt, welche Gruppen alle mit einem, zwei, oder mehreren Halogenatomen oder Amino-Gruppen substituiert sein können;
 R⁴ eine Hydroxy-Gruppe, eine Gruppe der Formel OPO₃R⁹₂ oder OSO₃R¹⁰ oder eine Heteroalkyl-Gruppe, die mindestens eine OH, NH₂, SO₃R¹⁰, PO₃R⁹₂ oder COOH Gruppe trägt, oder einen Ester einer natürlich vorkommenden Aminosäure oder ein Derivat derselben darstellt, wobei die Gruppen R⁹ unabhängig voneinander H, Alkyl, Cycloalkyl, Aryl oder Aralkyl darstellen, und wobei R¹⁰ H, Alkyl, Cycloalkyl, Aryl oder Aralkyl darstellt;
 R⁵ aus den folgenden Gruppen ausgewählt wird:



R^6 H, F, Cl oder OMe darstellt;

R^7 H, F, Cl, OH, NH_2 , eine substituierte oder unsubstituierte Alkyl-Gruppe oder eine substituierte oder unsubstituierte Heteroalkyl-Gruppe darstellt, oder

R^3 und R^7 über eine Alkyl-, eine Alkenyl-, oder eine Heteroalkyl-Gruppe verbunden sein können oder einen Teil einer Cycloalkyl- oder Heterocycloalkyl-Gruppe darstellen; in diesem Fall stellt R^3 kein H dar, und R^7 stellt kein H, F, OH, NH_2 oder Cl dar; und

R^8 eine C_{1-6} -Heteroalkyl-Gruppe, eine Heteroarylalkyl-Gruppe, eine Heteroalkylaryl-Gruppe oder eine Heteroalkyl-heteroaryl-Gruppe darstellt;

oder ein pharmazeutisch verträgliches Salz, Solvat, Hydrat oder eine Formulierung derselben.

2. Verbindungen nach Anspruch 1, wobei R^1 H darstellt.

3. Verbindungen nach Anspruch 1 oder 2, wobei R^2 F oder H darstellt.

4. Verbindungen nach einem der Ansprüche 1 bis 3, wobei R^3 eine Ethyl-, eine 2-Propyl-, eine C_3 - C_6 -Cycloalkyl-, eine Phenyl- oder eine Pyridyl-Gruppe darstellt, die jeweils alle mit einem, zwei, drei oder mehreren Fluor-Atomen oder Amino-Gruppen substituiert sein können.

5. Verbindungen nach einem der Ansprüche 1 bis 4, wobei R^3 eine Cyclopropyl-Gruppe darstellt.

6. Verbindungen nach einem der Ansprüche 1 bis 3, wobei R^7 und R^3 zusammen eine Brücke der Formel $-O-CH_2-N$ (Me)- oder $-O-CH_2-CH(Me)-$ bilden, wobei die bevorzugte Stereochemie am chiralen Zentrum diejenige ist, die eine (S)-Konfiguration in der Endverbindung ergibt.


7. Verbindungen nach einem der Ansprüche 1 bis 5, wobei R^7 H, F, Cl oder eine Methoxy-Gruppe darstellt, die mit einem, zwei oder drei Fluoratomen substituiert sein kann.

8. Verbindungen nach einem der Ansprüche 1 bis 5, wobei X N oder CH darstellt.

9. Verbindungen nach einem der Ansprüche 1 bis 8, wobei R^4 eine Hydroxy-Gruppe oder eine Gruppe der Formel OSO_3H , OPO_3H_2 , $OCH_2OPO_3H_2$, $OCOCH_2CH_2COOH$ oder einen Ester einer natürlich vorkommenden Aminosäure oder ein Derivat derselben darstellt.

10. Verbindungen nach einem der Ansprüche 1 bis 9, wobei R^8 eine Gruppe der Formel $-CH_2NHCOCH=CH-Aryl$, $-CH_2O-Heteroaryl$, $-CH_2NHSO_2Me$, $-CH_2NHCOOMe$, $-CH_2NHCOMe$, $-CH_2NHCS_2Me$, $-CH_2NHCSMe$, $-CH_2NHCSNH_2$, $-CH_2NHCSOMe$ oder $-NHCOMe$ darstellt.


11. Verbindungen nach einem der Ansprüche 1 bis 10, wobei R^5 die folgende Struktur aufweist:



12. Verbindungen nach einem der Ansprüche 1 bis 11, wobei Y CH oder N darstellt.
13. Verbindungen nach einem der Ansprüche 1 bis 12, wobei A ein C₁₋₆-Alkylen, C₂₋₆-Alkenylen, C₂₋₆-Alkinylen, C₁₋₆-Heteroalkylen, Cyclopropylen, Epoxid, Aziridin, Thioepoxid, Lactam oder Lacton darstellt, welche Gruppen alle substituiert sein können.
14. Verbindungen nach einem der Ansprüche 1 bis 12, wobei A eine Gruppe der Formel -CH₂CH₂-, -OCH₂-, -OCH₂CH₂-, -SCH₂-, -SCH₂CH₂-, -CH=CH-, -C≡C-, -CH(OH)CH(OH)- oder -CH(NH₂)CH(OH)- darstellt.
15. Mono-, Di- oder Trinatriumsalz einer Verbindung der Formel (I) nach einem der Ansprüche 1 bis 14 oder Mischungen derselben, insbesondere ein Mono-, Di- oder Trinatriumsalz einer Verbindung der Formel (I), wobei R⁴ OPO₃H₂ oder OSO₃H darstellt oder Mischungen derselben.
16. Pharmazeutische Zusammensetzungen, die eine Verbindung nach einem der Ansprüche 1 bis 15 und gegebenenfalls Träger und/oder Hilfsstoffe und/oder Streckmittel enthalten.
17. Verwendung einer Verbindung oder einer pharmazeutischen Zusammensetzung nach einem der Ansprüche 1 bis 16 für die Herstellung von Medikamenten zur Behandlung von bakteriellen Infektionen.

Revendications

1. Composés de formule (I)



dans laquelle

A est un groupe alkylène, un groupe alcénylène, un groupe alcynylène, un groupe hétéroalkylène, un groupe cycloalkylène, un groupe hétérocycloalkylène, un groupe arylène ou un groupe hétéroarylène, tous ces groupes pouvant être substitués ;

Q est CR⁴ ;

X est CR⁷ ou N ;

Y est CR⁶ ou N ;

n est 1, 2 ou 3 ;

m est 1, 2 ou 3 ;

R¹ est H, F, Cl, Br, I, OH, NH₂, un groupe alkyle ou un groupe hétéroalkyle ;


R² est H, F ou Cl ;

R³ est H, un groupe alkyle, un groupe alcényle, un groupe alcynyle, un groupe hétéroalkyle, un groupe cycloalkyle,

un groupe hétérocycloalkyle, un groupe aryle, un groupe hétéroaryle, un groupe alkylaryle ou un groupe hétéroarylalkyle ; tous ces groupes pouvant être substitués avec un, deux ou plus atomes d'halogène ou groupes amino ;

R⁴ est un hydroxy, un groupe de formule OPO₃R⁹₂ ou OSO₃R¹⁰ ou un groupe hétéroalkyle portant au moins un groupe OH, NH₂, SO₃R¹⁰, PO₃R⁹₂ ou COOH ou un ester d'acide aminé d'origine naturelle ou un dérivé de celui-ci, dans lequel les groupes R⁹ indépendamment les uns des autres sont H, un alkyle, un cycloalkyle, un aryle ou un aralkyle et dans lequel R¹⁰ est H, un alkyle, un cycloalkyle, un aryle ou un aralkyle ;

R⁵ est choisi parmi les groupes suivants :



R⁶ est H, F, Cl ou OMe ;

R⁷ est H, F, Cl, OH, NH₂, un groupe alkyle substitué ou non substitué ou un groupe hétéroalkyle substitué ou non substitué, ou

R³ et R⁷ peuvent être liés par l'intermédiaire d'un groupe alkylène, alcénylène ou hétéroalkylène ou faire partie d'un groupe cycloalkylène ou hétérocycloalkylène ; dans le cas où R³ n'est pas H et R⁷ n'est pas H, F, OH, NH₂ ou Cl ; et R⁸ est un groupe hétéroalkyle en C₁ à C₆, hétéroarylalkyle, hétéroalkylaryle ou hétéroalkylhétéroaryle ; ou un sel, un solvate, un hydrate ou une formule pharmacologiquement acceptable de ceux-ci.

2. Composés selon la revendication 1, dans lesquels R¹ est H.

3. Composés selon la revendication 1 ou 2, dans lesquels R² est F ou H.

4. Composés selon l'une quelconque des revendications 1 à 3, dans lesquels R³ est un groupe éthyle, 2-propyle, cycloalkyle en C₃ à C₆, phényle ou pyridyle ; tous pouvant être substitués avec un, deux, trois ou plus atomes de fluor ou groupes amino.

5. Composés selon l'une quelconque des revendications 1 à 4, dans lesquels R³ est un groupe cyclopropyle.

6. Composés selon l'une quelconque des revendications 1 à 3, dans lesquels R⁷ et R³ forment ensemble un pont de formule -O-CH₂-N(Me)- ou -O-CH₂-CH(Me)-, dans laquelle la stéréochimie préférée au niveau du centre chiral est celle donnant la configuration (S) dans le composé final.


7. Composés selon l'une quelconque des revendications 1 à 5, dans lesquels R⁷ est H, F, Cl ou un groupe méthoxy qui peut être substitué par un, deux ou trois atomes de fluor.

8. Composés selon l'une quelconque des revendications 1 à 5, dans lesquels X est N ou CH.

9. Composés selon l'une quelconque des revendications 1 à 8, dans lesquels R⁴ est un hydroxy ou un groupe de formule OSO₃H, OPO₃H₂, OCH₂OPO₃H₂, OCOCH₂CH₂COOH ou un ester d'acide aminé d'origine naturelle ou d'un dérivé de celui-ci.

10. Composés selon l'une quelconque des revendications 1 à 9, dans lesquels R⁸ est un groupe de formule -CH₂NHCOCH=CH-aryle, -CH₂O-hétéroaryle, -CH₂NHSO₂Me, -CH₂NHCOOMe, -CH₂NHCOMe, -CH₂NHCS₂Me, -CH₂NHCSMe, -CH₂NHCSNH₂, -CH₂NHCSOMe ou -NHCOMe.

11. Composés selon l'une quelconque des revendications 1 à 10, dans lesquels R⁵ possède la structure suivante :



12. Composés selon l'une quelconque des revendications 1 à 11, dans lesquels Y est CH ou N.

13. Composés selon l'une quelconque des revendications 1 à 12, dans lesquels A est un alkylène en C₁ à C₆, un alcénylène en C₂ à C₆, un alcynylène en C₂ à C₆, un hétéroalkylène en C₁ à C₆, un cyclopropylène, un époxyde, une aziridine, un thioépoxyde, un lactame ou une lactone, tous ces groupes pouvant être substitués.

14. Composés selon l'une quelconque des revendications 1 à 12, dans lesquels A est un groupe de formule -CH₂CH₂-, -OCH₂-, -OCH₂CH₂-, -SCH₂-, -SCH₂CH₂-, -CH=CH-, -C=C-, -CH(OH)CH(OH)- ou -CH(NH₂)CH(OH)-.

15. Sel de mono-, di- ou tri-sodium d'un composé de formule (I) selon l'une quelconque des revendications 1 à 14, ou leurs mélanges, en particulier un sel de mono-, di- ou tri-sodium d'un composé de formule (I), dans laquelle R⁴ est OPO₃H₂ ou OSO₃H ou leurs mélanges.

16. Compositions pharmaceutiques contenant un composé selon l'une quelconque des revendications 1 à 15 et facultativement des supports et/ou des adjuvants et/ou des diluants.

17. Utilisation d'un composé ou d'une composition pharmaceutique selon l'une quelconque des revendications 1 à 16 pour la fabrication de médicaments destinés au traitement des infections bactériennes.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 02059116 A [0002]
- WO 03002560 A [0002]
- WO 03031443 A [0002]
- WO 03032962 A [0002] [0074]
- WO 03064413 A [0043]
- WO 9803507 A [0047]
- WO 0204462 A [0054]
- WO 9624593 A [0078]
- WO 2000044376 A [0091]